SUPV3L1 and optic atrophy: The patient’s phenotype, characterized by neurological symptoms such as ataxia, spasticity, as well as optic atrophy, and skin abnormalities, aligns with previous reports but also extends the clinical variability of SUPV3L1-associated disorders.